Forward Pharma is a NASDAQ traded Danish biopharmaceutical company that since 2005 has been developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. We granted to Biogen an irrevocable license to all of our IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion on February 9, 2017. We have opportunities to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, the U.S. interference outcome, Hart-Scott-Rodino (HSR) antitrust clearance and the ‘355 opposition outcome in Europe.
Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark, in the heart of Medicon Valley. Since 2007 we have also operated out of a subsidiary, Forward Pharma GmbH, in Leipzig, Germany, and since August 2014 out of a subsidiary in the United States, Forward Pharma USA, LLC.
|03/01/17||Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen|
|COPENHAGEN, Denmark, March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen, M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017. He previously held the position of Executive Vice President at the Company.
Dr. Svendsen succeeds Peder M. Andersen, M.D., who has led the Company since 2012. Dr. Andersen will retain his role as Chief Operating Officer and serve until Septe... |
|02/09/17||Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen|
|COPENHAGEN, Denmark, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned subsidiaries of Biogen Inc. and certain other parties (the “License Agreement”).
On January 17, 2017 Forward entered into the License Agreement subject to the approval of its shareholders and certain... |
|02/01/17||Forward Pharma Announces Results of Extraordinary General Meeting|
|Forward obtains shareholder approval for Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017 (the “Extraordinary General Meeting”), the requisite two-thirds majority of the votes cast as well as the share capital represented at the Extraordinary General Meeting approved the entry into a Settle... |
|01/17/17||Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen|
|Biogen will pay Forward a non-refundable cash fee of $1.25 billion
Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory approvals
COPENHAGEN, Denmark, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has entered into a binding agreement with two wholly owne... |
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.|